Demographic and clinical association with the hypotensive outcome of needle revision and mitomycin C
Keywords:
filtration bleb; needle revision; mitomycin C; trabeculectomyAbstract
Objective: to identify the association between demographic and clinical variables with the five-year hypotensive outcome of needle revision and mitomycin C in encapsulated filtration blebs.
Methods: Prospective longitudinal descriptive study in 30 patients who underwent revision with needles and mitomycin C. Age, sex and skin color were identified, as well as intraocular pressure, number of eyes drops in the preoperative period, at one month, three months, a one year and five years postoperatively. The association between the variables was also determined
Results: The intraocular pressure at one month was lower compared to preoperative (p = 2.9x10-22); from one year on it increased up to five years, (22 ± 3 mmHg; p1-5years = 0.0016). There was an association between young, female and white skin color patients with postoperative intraocular pressure. Not so with the time after the trabeculectomy was performed.
Conclusions: Revision with a needle and mitomycin C reduces intraocular pressure up to five years postoperatively, but its effect decreases over time. Young, female, and white patients have a greater chance of reducing intraocular pressure. The time after the trabeculectomy was performed does not influence the final result.
Downloads
References
1. Tanna AP, Boland MV, Giaconi JA, Krishnan C, Lin SC, Medeiros FA. 2020-2021 Basic and Clinical Science Course(tm) (BCSC), Section 10: Glaucoma. San Francisco: American Academy of Ophthalmology; 2020.
2. Organización Mundial de la Salud (OMS). Ceguera O. Discapacidad visual. Nota Descriptiva No 282. Ginebra: OMS; 2014 [acceso 18/01/2023]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-visual-impairment
3. Barroso R, Rodríguez BN, Río M, Padilla CM, Martínez JG, Fumero FY, et al. Discapacidad visual y ceguera por catarata en Cuba en 2016. Rev Cub Oftalmol. 2022 [acceso 18/01/2023];35(4). Disponible en: https://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/1710
4. Keeffe J, Resnikoff S, Care SE. Prevalence and causes of vision impairment and blindness: the global burden of disease. In: Khanna R, Rao G, Marmamula S, editores. Innovative approaches in the delivery of primary and secondary eye care. Essentials in Ophthalmology. Springer Nature Link; 2019. pp. 7-20. DOI: https://doi.org/10.1007/978-3-319-98014-0_2
5. Wurster P, Harris A, Gonzalez AC, Adjei S, Verticchio A, Mathew S, et al. Risk factors for open-angle glaucoma in persons of Latin American descent. J Glaucoma. 2020;29(3):217-25. DOI: https://doi.org/10.1097/ijg.0000000000001429
6. Organización Nacional de Estadísticas e Información (ONEI). Anuario Estadístico de Cuba. 2019. La Habana, ONEI; 2019 [acceso 18/01/2023]. Disponible en: https://temas.sld.cu/estadisticassalud/2020/05/13/publicado-el-anuario estadistico-de-salud-2019/
7. Albizu-Campos JC. Cuba: envejecimiento demográfico y desarrollo humano. Econ Desarrollo. 2020 [acceso 18/01/2023];164(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0252-85842020000200013
8. Öhnell H, Bengtsson B, Heijl A. Making a correct diagnosis of glaucoma: data from the EMGT. J Glaucoma. 2019;28(10):859. DOI: https://doi.org/10.1097/ijg.0000000000001342
9. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open‐angle glaucoma blindness. Acta Ophthalmologica. 2014; 92(5):421-5. DOI: https://doi.org/10.1111/aos.12203
10. Mokhles P, van Gorcom L, Schouten JS, Berendschot TT, Beckers HJ, Webers CAJE. Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients ocular hypertension and glaucoma suspect patients. Eye. 2021;35(3):883-91. DOI: https://doi.org/10.1038/s41433-020-0991-0
11. Peters D, Heijl A, Andersson‐Geimer S, Aspberg J, Lindén C, Jóhannesson G, et al. Threat to fixation and vision‐related quality of life in early open‐angle glaucoma-results from the Glaucoma Intensive Treatment Study. Acta Ophthalmol. 2023;101(1):74-80. DOI: https://doi.org/10.1111/aos.15203
12. Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014;158(6):1121-9.e1. DOI: https://doi.org/10.1016/j.ajo.2014.08.023
13. Soh Z, Yu M, Betzler BK, Majithia S, Thakur S, Tham YC, et al. The global extent of undetected glaucoma in adults: a systematic review and meta-analysis. Ophthalmol. 2021;128(10):1393-404. DOI: https://doi.org/10.1016/j.ophtha.2021.04.009
14. Fernández L, Padilla C, Obret I, Piloto I, Fumero FY. Factores pronósticos de fracaso de la trabeculectomía en una población de Cuba. Arch Soc Esp Oftalmol. 2016;91(1):27-33. DOI: https://doi.org/10.1016/j.oftal.2015.09.004
15. Ahmadzadeh A, Kessel L, Subhi Y, Bach-Holm D. Comparative efficacy of phacotrabeculectomy versus trabeculectomy with or without later phacoemulsification: a systematic review with meta-analyses. J Ophthalmol. 2021;2021:1-17. DOI: https://doi.org/10.1155/2021/6682534
16. Panarelli JF, Do AT. Bleb management following trabeculectomy and glaucoma drainage device implantation. REV Ophthalmol. 2022;16(2):76-9. DOI: https://doi.org/10.17925/USOR.2022.16.2.76
17. Wolters JE, van Mechelen RJ, Al Majidi R, Pinchuk L, Webers CA, Beckers HJ, et al. History, presence, and future of mitomycin C in glaucoma filtration surgery. Curr Opin Ophthalmol. 2021;32(2):148-59. DOI: https://doi.org/10.1097/icu.0000000000000729
18. de Oliveira CM, Martins JL. Overview of cicatricial modulators in glaucoma fistulizing surgery. Int Ophthalmol. 2020;40(10):2789-96. DOI: https://doi.org/10.1007/s10792-020-01454-w
19. Ruparelia S, Rafuse PE, Eadie BD. Efficacy and safety of ab interno trabeculectomy revision with 5-fluorouracil in advanced glaucoma due to subconjunctival fibrosis. Can J Ophthalmol. 2024;59(2):e124-9. DOI: https://doi.org/10.1016/j.jcjo.2022.11.010
20. Gil-Carrasco F, Alvarez-Ascencio D, Tolosa-Tort P, Alvarez-Padilla M, Jimenez-Roman J, Castillejos-Chevez A. Outcomes of trabeculectomy with polyvinylpyrrolidone collagen versus mitomycin in primary open angle glaucoma. 36-month follow-up. Arch Soc Esp Oftalmol. 2021;96(4):202-9. DOI: https://doi.org/10.1016/j.oftal.2020.09.018
21. Rabiolo A, Marchese A, Bettin P, Monteduro D, Galasso M, Dolci MP, et al. Needle revision outcomes after glaucoma filtering surgery: survival analysis and predictive factors. Eur J Ophthalmol. 2019;30(2):350-9. DOI: https://doi.org/10.1177/1120672119830861
22. González-Ventosa A, Ariz-Juan J, Sabater-Cruz N. Medidas para prevenir los riesgos asociados con la exposición a citostáticos en cirugía filtrante de glaucoma. Arch Soc Esp Oftalmol. 2020;95(7):334-44.DOI: https://doi.org/10.1016/j.oftal.2020.04.018
23. Fumero FY, Cárdenas D, Fernández L, Piloto I, Vidal M, Obret I, et al. Revisión con aguja asociada a mitomicina C en ampollas de filtración encapsuladas. Rev Cub Oftalmol. 2016 [acceso 18/01/2023];29(2):189-98. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762016000200002
24. Fumero FY, Arzuaga E, Piloto I, Fernández L, Cárdenas D. Revisión con agujas y uso de bevacizumab en bulas de filtración encapsuladas. Rev Cub Oftalmol. 2017 [acceso 18/01/2023];30(4):1-11. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762017000400003
25. Ozturk E, Firat PG. Long-term effects of phacoemulsification surgery on intraocular pressure in patients with primary open-angle glaucoma and pseudoexfoliation glaucoma. Ann Med Research. 2020 [acceso 18/01/2023];27(8):2112-7. Disponible en: https://annalsmedres.org/index.php/aomr/article/view/902
26. Dorairaj SK, Kahook MY, Williamson BK, Seibold LK, ElMallah MK, Singh IP. A multicenter retrospective comparison of goniotomy versus trabecular bypass device implantation in glaucoma patients undergoing cataract extraction. Clin Ophthalmol. 2018;12:791-7. DOI: https://doi.org/10.2147/opth.s158403
27. Ávila AJV, Padilla JR. Glaucoma: aspectos relevantes. Rev Méd Sinerg. 2022 [acceso 18/01/2023];7(8):e880-e. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/880
28. Zarei R, Shahhosseini S, Faragee-Oskoueel G. Needle revision with Mitomycin-C in encapsulated Blebs. Acta Med Iran. 2008 [acceso 18/01/2023];46(4):295-7. Disponible en: https://acta.tums.ac.ir/index.php/acta/article/view/3486
29. Kahook MY. Needle bleb revision with bevacizumab. Techn Ophthalmol. 2008;6(4):111-3. DOI: https://doi.org/10.1097/ITO.0b013e318194edaf
30. Amini H, Esmaili A, Zarei R, Amini N, Daneshvar R. Office-based slit-lamp needle revision with adjunctive mitomycin-C for late failedorencapsulatedfilteringblebs. Middle East Afr J Ophthalmol. 2012;19(2):216-21. DOI: https://doi.org/10.4103/0974-9233.95255
31. Maestrini HA, Fernandes TA, Matoso HD, Amaral WO, Maestrini AA. Scleral injury caused by needling revision with adjunctive mytomicin-C: case report. Arq Bras Oftalmol. 2011;74(2):134-5.DOI: https://doi.org/10.1590/S0004-27492011000200015
32. Dalvi R, Orzech N, Kranemann C, Birt CM. Five-year results of 5-fluorouracil augmented needling revision of failing blebs. Ophthalmic Surg Lasers Imaging. 2012;43(1):32-8 DOI: https://doi.org/10.3928/15428877-20111129-02
33. Kim JS, Kim HJ, Na KI, Kim YK, Park KH, Jeoung JW. Comparison of efficacy and safety of bleb needle revision with and without 5-fluorouracil for failing trabeculectomy bleb. J Glaucoma. 2019;28(5):386-91. DOI: https://doi.org/10.1097/ijg.0000000000001226
34. Broadway DC, Bloom PA, Bunce C, Thiagarajan M, Khaw PT. Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: survival analysis. Ophthalmol. 2004;111(4):665-73. DOI: https://doi.org/10.1016/j.ophtha.2003.07.009
35. Gutiérrez-Ortiz C, Cabarga C, Teus MA. Prospective evaluation of preoperative factors associated with successful mitomycin C needling of failed filtration blebs. J Glaucoma. 2006;15(2):98-102. DOI: https://doi.org/10.1097/00061198-200604000-00004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Cubana de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
El contenido de la revista se encuentra accesible sin costo alguno. Está protegido por los términos de la Licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional
